$599

Novo London, Merck, Roche, and Sanofi Q4 ’23 Earnings; FDA Clears NeuroBo’s Obesity IND

Five cardiometabolic-related news items have been observed from Novo Nordisk, NeuroBo, Merck, Roche, and Sanofi. Below, FENIX provides the highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here